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Sickle Cell Disease and Variation in the PAR4 Receptor
Sickle cell disease disproportionately affects African Americans in the U.S. Much
can still be learned regarding determinants of frequency and severity of painful vasoocclusive episodes in these patients. It has been reported that a variant in PAR4 (proteaseactivated receptor 4) has a unique distribution among African Americans. One variant
(Thr120) is hyperactive, while the other (Ala120) is hypoactive. This receptor is present
on platelets, vascular cells, and nociceptors. We wish ultimately to test the hypothesis that
sickle cell patients with the hyperactive PAR4 receptor have greater pain severity. A
genotype-phenotype correlation would have prognostic value. An adequately powered
study to test this hypothesis would need to be multicenter. Therefore this is an ongoing
pilot feasibility study to 1) Determine whether a sufficient number of sickle cell patients
will consent to a focused genotype study; 2) Test if the current electronic health record
(EHR) can be queried for an accurate depiction of sickle cell-related pain treatment; and 3)
Collect single-center data on the genotype-phenotype correlation that can later be expanded
to a multi-center study. 7/18 patients asked have consented to be in the study, the EHR in
5/7 enrolled has matched self-reported healthcare visits for vaso-occlusive episodes, and
genetic studies are not being conducted until there are adequate numbers of samples. These
in-progress results indicate patients will consent at an acceptable frequency and that the
EHR is useful in objectively categorizing pain-severity phenotypes. Regardless of the date
from the genetic component, preliminary results suggest a multi-center study could be
productive.

